PMID- 10676909
OWN - NLM
STAT- MEDLINE
DCOM- 20000225
LR  - 20211203
IS  - 0037-1963 (Print)
IS  - 0037-1963 (Linking)
VI  - 37
IP  - 1
DP  - 2000 Jan
TI  - Current status of allogeneic bone marrow transplantation in acquired aplastic 
      anemia.
PG  - 30-42
AB  - Bone marrow transplantation is an effective therapy for aplastic anemia. Infusion 
      of allogeneic hematopoietic stem cells after high-dose immune suppression 
      restores normal hematopoiesis in most patients and long-term follow-up has 
      confirmed the durability of donor hematopoiesis. However, success of this 
      approach is limited by transplant-related complications, such as graft failure, 
      graft-versus-host disease, and various organ toxicities. Long-term survival rates 
      range from less than 40% to more than 90% in reported series. These rates have 
      improved over the past 20 years due to significant reductions in 
      graft-versus-host disease, interstitial pneumonitis, and early transplant-related 
      mortality. Most long-term survivors have excellent performance status. Late 
      effects such as cataracts, thyroid disorders, joint problems, and therapy-related 
      cancers are observed, especially in patients who received radiation for 
      pretransplant conditioning. Results are best in young patients transplanted with 
      bone marrow from a human leukocyte antigen (HLA)-identical sibling; early 
      transplantation is appropriate in this group. For older patients or those without 
      an HLA-identical related donor, transplants are better reserved for those who 
      fail to respond to immunosuppressive therapy.
FAU - Horowitz, M M
AU  - Horowitz MM
AD  - International Bone Marrow Transplant Registry, Health Policy Institute, Medical 
      College of Wisconsin, Milwaukee 53226, USA.
LA  - eng
GR  - CP-21161/CP/NCI NIH HHS/United States
GR  - P01-CA-40053/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Semin Hematol
JT  - Seminars in hematology
JID - 0404514
SB  - IM
MH  - Anemia, Aplastic/*surgery/therapy
MH  - *Bone Marrow Transplantation/adverse effects
MH  - Graft Rejection
MH  - Graft vs Host Disease
MH  - Histocompatibility
MH  - Humans
MH  - Immunosuppression Therapy
MH  - Survival Rate
MH  - Transplantation, Homologous
MH  - Twins, Monozygotic
RF  - 93
EDAT- 2000/02/17 09:00
MHDA- 2000/03/04 09:00
CRDT- 2000/02/17 09:00
PHST- 2000/02/17 09:00 [pubmed]
PHST- 2000/03/04 09:00 [medline]
PHST- 2000/02/17 09:00 [entrez]
AID - S0037196300000044 [pii]
AID - 10.1016/s0037-1963(00)90028-3 [doi]
PST - ppublish
SO  - Semin Hematol. 2000 Jan;37(1):30-42. doi: 10.1016/s0037-1963(00)90028-3.